Field 2 definition

Field 2. State the full legal name, address (including country) of the consignee. Field 3: Marks and numbers on the packages. Field 4: Number and kind of packages. Field 5: Provide a full description of each good. The description should be sufficient to relate it to the invoice description and to the Harmonized System (HS) description of the good. If the Certificate of Origin covers a single shipment of a good, include the invoice number as shown on the commercial invoice.
Field 2 means the Buccal Delivery of an Additional Compound for the treatment of prostate cancer and endometriosis and/or the suppression of testosterone and estrogen.
Field 2. State the full name, address and country of the importer. As defined in subparagraph (f) of Article 28, “importer” means a person who imports a good into the importing Party (e.g. the consignee who declares the importation). Field 3: Provide the name of loading port, transit port and discharging port and, the name of vessel / flight number, as far as known. Field 4: Provide item number (as necessary), marks and numbers of packages, number and kind of packages, HS tariff classification number as amended on January 1, 2002 and description of each good consigned. For each good, the HS tariff classification number should be indicated at the six-digit level. The description of the good on the certificate of origin should be substantially identical to the description on the invoice and, if possible, to the description under the HS for the good. With respect to subheading 2103.90, 2208.90, 4601.20 and 4601.91, in an exceptional case where the good is a specific product requiring a special description (e.g. instant ▇▇▇▇▇ and Igusa goods), such description of specific products should be indicated. With respect to each good of Chapter 50 through 63 of the HS, the materials of the other Party or non-Parties which are member countries of the ASEAN, the processes or operations conducted in such Party or non-Parties, and the names of such Party or non-Parties should be indicated (if such materials were used in the production of the good). Field 5: For each good, state which preference criterion (A through C under Preference Criteria above) is applicable. The rules of origin are contained in Chapter 3 and Annex 2. Note: In order to be entitled to preferential tariff treatment, each good of a Party should meet at least one of the criteria given. Indicate “ACU” for accumulation, “DMI” for de minimis and “FGM” for fungible goods or materials, if applicable. Field 6: For each good, indicate the quantity or weight. Field 7: Indicate the invoice number and date for each good. The invoice should be the one issued for the importation of the good into the importing Party. If the invoice is issued by a person different from the exporter to whom the certificate of origin is issued and the person who issues the invoice is located in a non-Party, it should be indicated in field 8 that the goods will be invoiced in a non-Party, identifying the full legal name and address of the person that issues the invoice. In an exceptional case where the number of the invoice issued in a non-Party...

Examples of Field 2 in a sentence

  • Field 2: If one producer, state the full legal name, address (including country, telephone number, fax number and email address) and legal tax identification number, as defined in Field 1, of said producer.

  • Field 1, Field 2, Field 3, T1-4, Lions Field, and multi-use field: Use the further west County Road 50 entrance.

  • The "Field" of this Agreement shall mean the following fields: Field 1: dietary supplements, sports performance enhancing products, foods with health claims, such as energy bar, skin care/cosmetic products; Field 2: food or drink products requiring FDA approval; Field 3: consumer foods, such as margarine, yogurt, and cereal; Field 4: research.

  • Cougar Softball Field #1 and Cougar Softball Field #2 : Feb-end of May: AHS softball: after school until 5:30* pm, Monday –Friday.

  • During the term of the license, Terragen will [*****] to [*****] under [*****] in Field 2 to [*****].


More Definitions of Field 2

Field 2 means the diagnosis, prevention and treatment of disease in humans OTHER THAN: (a) by the delivery of a Licensed Product directly [***], or (b) by the delivery of a Licensed Product [***], or (c) by use of a Licensed Product to target [***].
Field 2 means cellular banking.
Field 2. Manufacturing, Sale and Distribution of KLHsu as an immunogenic carrier protein in cancer vaccines except the Manufacturing, Sale and Distribution of KLHsu as an immunogenic carrier protein in autologous NHL-Vaccines. For the avoidance of doubt, the term “Field 2” does not include sale (or resale) of KLHsu alone but relates to the manufacturing, sale and distribution of KLHsu as a part of cancer vaccines.
Field 2 means all fields except Field 1.
Field 2 means vaccines for the therapeutic treatment of Triple Negative Breast Cancer (TNBC) and other breast cancers, which express the a-lactalbumin protein.
Field 2 means vaccines for the therapeutic treatment of Ovarian Cancer and other cancers, which express the Anti-Mullerian Hormone Receptor 2 (AMHR2) protein, including an Anti-Mullerian Hormone Receptor 2 protein with an extracellular domain (AMHR2-ED).
Field 2 means in vitro testing or monitoring of PT/INR, *[REDACTED], in each case, solely in the ambulatory care market segment, which includes, without limitation, out-patient clinics, rural clinics, pharmacy clinics, company-sponsored clinics, doctor’s offices, group practices, nursing homes, senior facilities, board-and-care facilities, and other entities that purchase test strips for PT/INR, *[REDACTED], independently of a hospital purchasing system. For the avoidance of doubt, the Field excludes in vitro testing or monitoring of PT/INR, *[REDACTED], (a) in the at-home testing or patient self-testing market segments, or (b) in any Independent Diagnostic Testing Facility as defined by the U.S. Code of Federal Regulations 42 CFR 410.33(a)(1). * Confidential portion has been omitted and has been filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.